Players That Evolve In Tandem With China's Health System Reforms Will Survive and Prosper, Says Pfizer Executive
This article was originally published in PharmAsia News
Executive Summary
BEIJING - With China's entire healthcare environment set to undergo rapid-fire change, propelled by system-wide reforms slated to be progressively implemented over the next decade, players that are the nimblest at adapting to or even promoting the transformation will emerge as the strongest winners
You may also be interested in...
Eager To Counter Patent Cliff, Falling Share Price, Pfizer Forges New Partnerships Around The World, Inside China
BEIJING - The New York-headquartered Pfizer Inc. entered into an agreement with the Osaka-based Takeda Pharmaceutical to co-promote Takeda's diabetes drug Actos (pioglitazone) inside China in part because the American outfit can rely on its vastly expanded sales network here following its merger with Wyeth
Eager To Counter Patent Cliff, Falling Share Price, Pfizer Forges New Partnerships Around The World, Inside China
BEIJING - The New York-headquartered Pfizer Inc. entered into an agreement with the Osaka-based Takeda Pharmaceutical to co-promote Takeda's diabetes drug Actos (pioglitazone) inside China in part because the American outfit can rely on its vastly expanded sales network here following its merger with Wyeth
Pharmaceutical Revenues In China Rising Faster Than Projected
HONG KONG - A recent report by Chinese firm Wicon International suggests revenues from pharmaceutical products in China this year could grow by $12 billion to $82 billion. Total sales in 2008 amounted to about $70 billion